Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Debt Repayments (2016 - 2026)

Amphastar Pharmaceuticals has reported Long-Term Debt Repayments over the past 13 years, most recently at $104000.0 for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 9.57% year-over-year to $104000.0; the TTM value through Dec 2025 reached $223000.0, down 97.3%, while the annual FY2025 figure was $223000.0, 97.3% down from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $104000.0 at Amphastar Pharmaceuticals, up from $44000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $200.1 million in Q3 2023 and troughed at $37000.0 in Q2 2025.
  • A 5-year average of $18.3 million and a median of $565500.0 in 2022 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 39081.25% in 2023 and later tumbled 99.98% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $613000.0 in 2021, then crashed by 79.12% to $128000.0 in 2022, then skyrocketed by 39081.25% to $50.2 million in 2023, then crashed by 99.77% to $115000.0 in 2024, then dropped by 9.57% to $104000.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for AMPH at $104000.0 in Q4 2025, $44000.0 in Q3 2025, and $37000.0 in Q2 2025.